



Wednesday, April 9, 2025		
8:00-9:00 am	Registration, Continental Breakfast, and Poster Set up	
9:00-9:10 am	Opening Remarks	
	Sanjay V. Malhotra, Ph.D., FRSC	
	Director, Center for Experimental Therapeutics	
	Steve Stadum, J.D. OHSU Interim President	
Session I:	Keynote Lecture	
9:10-9:45 am	Moderator: Sanjay Malhotra, Ph.D.	
9:10-9:45am	Dr. H. Michael Shepard	
	Lasker Awardee 2019	
	The Evolution of Antibody-Based Therapeutics Academic Drug Discovery: Opportunities and Challenges	
Session II:	Moderator: Mary Heinricher, Ph.D.	
9:55-11:10 am	Senior Associate Dean; OHSU School of Medicine	
9:55-10:15 am	Nabil Alkayed, M.D., Ph.D.	
	Professor and Director of Research, OHSU Knight Cardiovascular Institute	
	GPR39 as a Therapeutic Target in Subarachnoid Hemorrhage Kelly Monk, Ph.D.	
10:15-10:35 am	Professor and co-director, OHSU Vollum Institute	
	In vivo drug screens to find modulators of myelination	
10:35-10:50 am	Susan Hayflick, M.D., Ph.D.	
	Professor MMG, Pediatrics, and Neurology; Chair MMG, OHSU School of Medicine	
	Precision medicine for a lethal inborn error of vitamin metabolism	
	Victor DeFilippis, Ph.D. Associate Professor, OHSU VGTI-Vaccine and Gene Therapy Institute	
	A novel human selective STING agonist with anti-tumor properties in a mouse model	
11:10-11:30 am	Coffee Break and Poster Session	
Session III:	Artificial Intelligence (AI) and Machine Learning Based Drug Discovery	
11:30-12:30 pm	Moderator: Lisa Coussens, Ph.D.	
	D	
	Deputy Director, Basic & Translational Research, OHSU Knight Cancer Institute	
	Shannon McWeeney, Ph.D.	
11:30-11:50 am		
11:30-11:50 am	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies	
	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D.	
11:30-11:50 am	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc.	
	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery	
	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc.	
11:50:12:10 am	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy	
11:50:12:10 am	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc.	
11:50:12:10 am 12:10:12:30 am	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D.	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm Session IV:	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic Moderator: Shivaani Kummar, M.D., Interim Chief Exec, OHSU Knight Cancer Institute	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm Session IV:	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic Moderator: Shivaani Kummar, M.D., Interim Chief Exec, OHSU Knight Cancer Institute Gordon Mills, M.D., Ph.D. Director, Precision Oncology, OHSU Knight Cancer Institute	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm Session IV: 2:10-3:10 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic Moderator: Shivaani Kummar, M.D., Interim Chief Exec, OHSU Knight Cancer Institute Gordon Mills, M.D., Ph.D. Director, Precision Oncology, OHSU Knight Cancer Institute Translating Bench Science to the Clinic	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm Session IV: 2:10-3:10 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic Moderator: Shivaani Kummar, M.D., Interim Chief Exec, OHSU Knight Cancer Institute Gordon Mills, M.D., Ph.D. Director, Precision Oncology, OHSU Knight Cancer Institute Translating Bench Science to the Clinic Lee Neilson, M.D.	
11:50:12:10 am 12:10:12:30 am 12:30-2:00 pm 2:00 -2:10 pm Session IV: 2:10-3:10 pm	Shannon McWeeney, Ph.D. Director, Medical Bioinformatics, OHSU Knight Cancer Institute Triangulating Innovation: Bridging AI, Multi-Omics, and Unmet Clinical Needs for Next-Generation Therapies Leah Frye, Ph.D. Founder, LLFrye Consulting; Senior Advisor, Health Tech Innovations, Inc. From Computer Aided Drug Discovery to Computer Driven Drug Discovery Rajat Roy CEO and Co-Founder, PathomIQ Inc. Interpretable AI powered Multiomics Platform for Advancing Precision Medicine Networking Lunch and Poster Session Afternoon Introduction Nathan Selden, M.D., Ph.D. Dean, OHSU School of Medicine Translating Discoveries: Lab to Clinic Moderator: Shivaani Kummar, M.D., Interim Chief Exec, OHSU Knight Cancer Institute Gordon Mills, M.D., Ph.D. Director, Precision Oncology, OHSU Knight Cancer Institute Translating Bench Science to the Clinic	





2:50-3:10 pm	Ronan Swords, M.D., Ph.D. Division of Hematology/Medical Oncology, OHSU Crossing the Valley of Death: Lessons from Acute Myeloid Leukemia
3:10-3:25 pm	Coffee Break and Poster Session
Session V: 3:25-4:25 pm	Academia to Start Ups Moderator: Marc Freeman, Ph.D., Director, OHSU Vollum Institute
3:25-3:45 pm	David K. Thomas, M.D. Harvard University Founder, Cerise Reverse Translating Deep Human Biology for Effective Drug Development
3:45-4:05 pm	Shilpa Sambashivan, Ph.D. CEO, Nura Bio From Flies to Humans: SARM1 Inhibition as a Neuroprotective Therapeutic Strategy
4:05-4:25 pm	Craig Stolarczyk, MS Co-founder & CEO, SynPlexity DBTL: Enabling Biomedical Innovation at Scale
Session VI: 4:25-5:25 pm	Investing in Discovery Moderator: Travis Cook; Senior Director, Technology Transfer, OHSU and Sanjay Malhotra, Ph.D. Director, Center for Experimental Therapeutics
4:25-5:25 pm	Panelists: Joe Horsman, Michael Phillips, Jack Gomer, Shula Jaron, Angelica Parente
5:25-5:30 pm	Closing Remarks
	Sanjay V. Malhotra, Ph.D.
5:30-6:30pm	Wine and Cheese Reception and Networking

Thanks to our sponsors





















Thanks to our media partners



